• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 3. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 4. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

Ethyl 5-(4-methylphenyl)-2H-pyrazole-3-carboxylate (CAS No. 595610-41-6): A Comprehensive Overview

Ethyl 5-(4-methylphenyl)-2H-pyrazole-3-carboxylate (CAS No. 595610-41-6) is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound, characterized by its intricate molecular structure, exhibits a unique combination of pharmacological properties that make it a promising candidate for further exploration in drug development. The Ethyl 5-(4-methylphenyl)-2H-pyrazole-3-carboxylate molecule, with its fused heterocyclic system, offers a versatile platform for designing novel therapeutic agents targeting various biological pathways.

The chemical structure of this compound consists of a pyrazole core substituted with an ethyl ester group and a 4-methylphenyl (para-methylbenzene) moiety. This arrangement imparts specific electronic and steric properties, which are critical for its interaction with biological targets. The pyrazole ring is a well-known pharmacophore in medicinal chemistry, frequently incorporated into drugs due to its ability to modulate enzyme activity and receptor binding. The presence of the ester group enhances the solubility and bioavailability of the compound, making it more amenable for formulation into pharmaceutical products.

Recent advancements in computational chemistry and molecular modeling have enabled researchers to predict the potential biological activities of Ethyl 5-(4-methylphenyl)-2H-pyrazole-3-carboxylate with greater accuracy. Studies have indicated that this compound may exhibit inhibitory effects on certain kinases and enzymes implicated in inflammatory and metabolic disorders. The methylphenyl substituent, in particular, has been shown to influence the compound's binding affinity and selectivity, making it a valuable scaffold for structure-activity relationship (SAR) studies.

In the realm of drug discovery, the synthesis of derivatives of Ethyl 5-(4-methylphenyl)-2H-pyrazole-3-carboxylate has been extensively explored. Researchers have modified various functional groups within the molecule to optimize its pharmacological profile. For instance, replacing the ethyl ester with other ester or amide functionalities has been shown to alter the compound's metabolic stability and pharmacokinetic properties. These modifications are crucial for developing drugs that exhibit improved efficacy and reduced side effects.

The synthesis of Ethyl 5-(4-methylphenyl)-2H-pyrazole-3-carboxylate involves multi-step organic reactions, typically starting from readily available precursors such as 4-methylbenzaldehyde and hydrazine hydrate. The pyrazole core is formed through a condensation reaction, followed by esterification to introduce the ethyl carboxylate group. Advanced synthetic techniques, including palladium-catalyzed cross-coupling reactions, have been employed to enhance yield and purity. These methods align with modern green chemistry principles, emphasizing sustainability and minimal waste generation.

The pharmacological evaluation of Ethyl 5-(4-methylphenyl)-2H-pyrazole-3-carboxylate has revealed intriguing potential in several therapeutic areas. Preclinical studies have demonstrated its ability to modulate inflammatory pathways by inhibiting key enzymes such as COX-2 and LOX. Additionally, the compound has shown promise in preclinical models of metabolic disorders by interacting with receptors involved in glucose homeostasis. These findings underscore the compound's versatility as a lead molecule for drug development.

The role of computational tools in understanding the pharmacological behavior of Ethyl 5-(4-methylphenyl)-2H-pyrazole-3-carboxylate cannot be overstated. Molecular dynamics simulations have provided insights into how the compound interacts with biological targets at an atomic level. These simulations help predict binding affinities and identify potential binding pockets on enzymes or receptors. Such information is invaluable for designing next-generation drugs with enhanced specificity and potency.

The future prospects of Ethyl 5-(4-methylphenyl)-2H-pyrazole-3-carboxylate in pharmaceutical research are promising. Ongoing studies aim to explore its potential as an antiviral agent by targeting viral proteases and polymerases. Furthermore, researchers are investigating its role in neurodegenerative diseases by assessing its interactions with amyloid-beta plaques and tau proteins. These investigations highlight the compound's broad therapeutic applicability.

In conclusion, Ethyl 5-(4-methylphenyl)-2H-pyrazole-3-carboxylate (CAS No. 595610-41-6) represents a significant advancement in pharmaceutical chemistry due to its unique structural features and promising biological activities. The integration of synthetic chemistry, computational modeling, and preclinical research continues to unravel its full potential as a therapeutic agent. As scientific understanding progresses, this compound is poised to play a crucial role in developing innovative treatments for various human diseases.

• 5932-30-9(Ethyl 3-phenyl-1H-pyrazole-5-carboxylate)
• 13599-12-7(Ethyl 3-phenylpyrazole-5-carboxylate)
• 56426-35-8(Methyl 3-phenyl-1H-pyrazole-5-carboxylate)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)